Literature DB >> 21690241

The poly-γ-D-glutamic acid capsule of Bacillus anthracis enhances lethal toxin activity.

Jeyoun Jang1, Minhui Cho, Jeong-Hoon Chun, Min-Hee Cho, Jungchan Park, Hee-Bok Oh, Cheon-Kwon Yoo, Gi-eun Rhie.   

Abstract

The poly-γ-D-glutamic acid (PGA) capsule is one of the major virulence factors of Bacillus anthracis, which causes a highly lethal infectious disease. The PGA capsule disguises B. anthracis from immune surveillance and allows its unimpeded growth in the host. The PGA capsule recently was reported to be associated with lethal toxin (LT) in the blood of experimentally infected animals (M. H. Cho, et al., Infect. Immun. 78:387-392, 2010). The effect of PGA, either alone or in combination with LT, on macrophages, which play an important role in the progression of anthrax disease, has not been thoroughly investigated. In this study, we investigated the effect of PGA on LT cytotoxicity using the mouse macrophage cell line J774A.1. PGA produced a concentration-dependent enhancement of the cytotoxicity of LT on J774A.1 cells through an enhancement in the binding and accumulation of protective antigen to its receptors. The increase of LT activity was confirmed using Western blot analysis, which showed that the combination of PGA and LT produced a greater degree of degradation of mitogen-activated protein kinase kinases and an increased level of the activation of the proform of caspase-1 to its processed form compared to the effects of LT alone. In addition, mice that received a tail vein injection of both PGA and LT had a significantly increased rate of death compared to that of mice injected with LT alone. PGA had no effect when added to cultures or administered to mice in the absence of LT. These results emphasize the importance of PGA in the pathogenesis of anthrax infection.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21690241      PMCID: PMC3165481          DOI: 10.1128/IAI.01145-10

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  37 in total

Review 1.  Anthrax toxins: a weapon to systematically dismantle the host immune defenses.

Authors:  Jean-Nicolas Tournier; Silvia Rossi Paccani; Anne Quesnel-Hellmann; Cosima T Baldari
Journal:  Mol Aspects Med       Date:  2009-06-26

2.  Expression and secretion of the protective antigen of Bacillus anthracis in Bacillus brevis.

Authors:  Gi-Eun Rhie; Young-Mia Park; Jeong-Hoon Chun; Cheon-Kwon Yoo; Won-Keun Seong; Hee-Bok Oh
Journal:  FEMS Immunol Med Microbiol       Date:  2005-08-01

3.  Protection against anthrax lethal toxin challenge by genetic immunization with a plasmid encoding the lethal factor protein.

Authors:  B M Price; A L Liner; S Park; S H Leppla; A Mateczun; D R Galloway
Journal:  Infect Immun       Date:  2001-07       Impact factor: 3.441

4.  Detection of anthrax toxin in the serum of animals infected with Bacillus anthracis by using engineered immunoassays.

Authors:  Robert Mabry; Kathleen Brasky; Robert Geiger; Ricardo Carrion; Gene B Hubbard; Stephen Leppla; Jean L Patterson; George Georgiou; B L Iverson
Journal:  Clin Vaccine Immunol       Date:  2006-06

Review 5.  Manipulation of host signalling pathways by anthrax toxins.

Authors:  Benjamin E Turk
Journal:  Biochem J       Date:  2007-03-15       Impact factor: 3.857

6.  Serum lipoproteins attenuate macrophage activation and Toll-Like Receptor stimulation by bacterial lipoproteins.

Authors:  Sylvette Bas; Richard W James; Cem Gabay
Journal:  BMC Immunol       Date:  2010-09-16       Impact factor: 3.615

7.  Effect of the lower molecular capsule released from the cell surface of Bacillus anthracis on the pathogenesis of anthrax.

Authors:  Sou-Ichi Makino; Masahisa Watarai; Hyeng-Il Cheun; Toshikazu Shirahata; Ikuo Uchida
Journal:  J Infect Dis       Date:  2002-06-27       Impact factor: 5.226

8.  A dually active anthrax vaccine that confers protection against both bacilli and toxins.

Authors:  Gi-Eun Rhie; Michael H Roehrl; Michael Mourez; R John Collier; John J Mekalanos; Julia Y Wang
Journal:  Proc Natl Acad Sci U S A       Date:  2003-09-05       Impact factor: 11.205

9.  Detection of anthrax toxin by an ultrasensitive immunoassay using europium nanoparticles.

Authors:  Shixing Tang; Mahtab Moayeri; Zhaochun Chen; Harri Harma; Jiangqin Zhao; Haijing Hu; Robert H Purcell; Stephen H Leppla; Indira K Hewlett
Journal:  Clin Vaccine Immunol       Date:  2009-01-07

10.  Association of Bacillus anthracis capsule with lethal toxin during experimental infection.

Authors:  J W Ezzell; T G Abshire; R Panchal; D Chabot; S Bavari; E K Leffel; B Purcell; A M Friedlander; W J Ribot
Journal:  Infect Immun       Date:  2008-12-08       Impact factor: 3.441

View more
  18 in total

1.  Revisiting the Concept of Targeting Only Bacillus anthracis Toxins as a Treatment for Anthrax.

Authors:  Itai Glinert; Elad Bar-David; Assa Sittner; Shay Weiss; Josef Schlomovitz; Amir Ben-Shmuel; Adva Mechaly; Zeev Altboum; David Kobiler; Haim Levy
Journal:  Antimicrob Agents Chemother       Date:  2016-07-22       Impact factor: 5.191

2.  Human monoclonal antibodies generated following vaccination with AVA provide neutralization by blocking furin cleavage but not by preventing oligomerization.

Authors:  Kenneth Smith; Sherry R Crowe; Lori Garman; Carla J Guthridge; Jennifer J Muther; Emily McKee; Nai-Ying Zheng; A Darise Farris; Joel M Guthridge; Patrick C Wilson; Judith A James
Journal:  Vaccine       Date:  2012-03-14       Impact factor: 3.641

3.  Poly-γ-glutamic acid productivity of Bacillus subtilis BsE1 has positive function in motility and biocontrol against Fusarium graminearum.

Authors:  Luyao Wang; Ning Wang; Dandan Mi; Yuming Luo; Jianhua Guo
Journal:  J Microbiol       Date:  2017-06-30       Impact factor: 3.422

Review 4.  The Bacillus cereus Group: Bacillus Species with Pathogenic Potential.

Authors:  Monika Ehling-Schulz; Didier Lereclus; Theresa M Koehler
Journal:  Microbiol Spectr       Date:  2019-05

5.  Human Innate Immune Cells Respond Differentially to Poly-γ-Glutamic Acid Polymers from Bacillus anthracis and Nonpathogenic Bacillus Species.

Authors:  Tanya M Jelacic; Wilson J Ribot; Jennifer Chua; Anne E Boyer; Adrian R Woolfitt; John R Barr; Arthur M Friedlander
Journal:  J Immunol       Date:  2020-01-13       Impact factor: 5.422

6.  The Poly-γ-d-Glutamic Acid Capsule Surrogate of the Bacillus anthracis Capsule Is a Novel Toll-Like Receptor 2 Agonist.

Authors:  Jun Ho Jeon; Hae-Ri Lee; Min-Hee Cho; Ok-Kyu Park; Jungchan Park; Gi-eun Rhie
Journal:  Infect Immun       Date:  2015-07-20       Impact factor: 3.441

Review 7.  Genetic and metabolic engineering for poly-γ-glutamic acid production: current progress, challenges, and prospects.

Authors:  Zheng Zhang; Penghui He; Dongbo Cai; Shouwen Chen
Journal:  World J Microbiol Biotechnol       Date:  2022-08-28       Impact factor: 4.253

8.  Anthrax toxin protective antigen integrates poly-γ-D-glutamate and pH signals to sense the optimal environment for channel formation.

Authors:  Alexander F Kintzer; Iok I Tang; Adam K Schawel; Michael J Brown; Bryan A Krantz
Journal:  Proc Natl Acad Sci U S A       Date:  2012-10-24       Impact factor: 11.205

Review 9.  Anthrax prophylaxis: recent advances and future directions.

Authors:  E Diane Williamson; Edward Hugh Dyson
Journal:  Front Microbiol       Date:  2015-09-24       Impact factor: 5.640

10.  Alveolar macrophages infected with Ames or Sterne strain of Bacillus anthracis elicit differential molecular expression patterns.

Authors:  Felicia D Langel; Chih-Yuan Chiang; Douglas Lane; Tara Kenny; Jenifer F Ojeda; Yang Zhong; Jianwei Che; Yingyao Zhou; Wilson Ribot; Krishna P Kota; Sina Bavari; Rekha G Panchal
Journal:  PLoS One       Date:  2014-02-07       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.